Lexicon Pharmaceuticals
LXRX
123 hedge funds and large institutions have $627M invested in Lexicon Pharmaceuticals in 2014 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 47 increasing their positions, 19 reducing their positions, and 13 closing their positions.
154% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 13
147% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 19
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
18% more funds holding
Funds holding: 104 → 123 (+19)
5% less capital invested
Capital invested by funds: $657M → $627M (-$30.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
+$172M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$34.4M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$12.6M |
| 4 |
MCM
Masters Capital Management
Atlanta,
Georgia
|
+$9.21M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$5.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$1.51M |
| 2 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$164K |
| 3 |
GF
Gabelli Funds
Rye,
New York
|
-$116K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$111K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$100K |
LXRX Hedge Fund Activity: Q4 2014 in Review
123 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q4 2014, worth a combined $627M — down 4.6% from $657M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new LXRX positions and 13 closed out — a net gain of 20 holders — while 47 added to existing stakes and 19 trimmed.
The largest buyer was Artal Group, adding an estimated $172M. The largest seller was Norges Bank, cutting an estimated $1.51M.
- 123 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q4 2014, up from 104 in Q3 2014.
- Funds reported $627M of Lexicon Pharmaceuticals stock for Q4 2014, down 4.6% quarter-over-quarter.
- 33 funds opened new Lexicon Pharmaceuticals positions in Q4 2014 and 13 closed out, a net change of +20 holders.
- The largest Lexicon Pharmaceuticals buyer in Q4 2014 was Artal Group, an estimated $172M added.
- The largest Lexicon Pharmaceuticals seller in Q4 2014 was Norges Bank, an estimated $1.51M sold.
Based on aggregated 13F filings for Q4 2014.